secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2024-06-11T23:59:59+00:00
Accession:  0000950170-24-071960
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Therapeutics stockholders elect directors, ratify auditor, approve executive compensation at 2024 annual meeting
--------------------------------------------------------------------------------

- Re-elected Herriot Tabuteau (33.3M for, 0.5M withheld) and Mark Coleman (27.1M for, 6.7M withheld) as Class III directors.
- Ratified Deloitte & Touche as independent auditor for FY2024 with 39.1M for, 0.15M against.
- Advisory vote approved named executive officer compensation: 32.9M for, 0.87M against.
- Approximately 84% of eligible shares (39.9M of 47.5M) were represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024071960/0000950170-24-071960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024071960/axsm-20240607.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-071960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer